In support, a recent paper posits that oxaliplatin, a third-generation platinum derivative chemotherapeutic agent, may also induce the aforementioned small change in proton affinity or a “proton affinity switch” on Piezo2, leading to Piezo2 channelopathy, due to the enigmatic high-proton-affinity nature of platinum [2]. Here, PIEZO2 is linked to channelopathy.